<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949284</url>
  </required_header>
  <id_info>
    <org_study_id>081603</org_study_id>
    <secondary_id>NCI-2016-01496</secondary_id>
    <secondary_id>Pro20160000563</secondary_id>
    <secondary_id>081603</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT02949284</nct_id>
  </id_info>
  <brief_title>Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery</brief_title>
  <official_title>Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works
      with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone
      in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause
      the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist
      ARN-509, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may
      fight prostate cancer by lowering the levels of androgen the body makes. Prednisone may
      either kill the tumor cells or stop them from dividing. Giving androgen receptor agonist
      ARN-509 with or without abiraterone acetate, GnRH agonist and prednisone may work better in
      treating patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the effect of neoadjuvant androgen receptor antagonist ARN-509 (apalutamide)
      with or without abiraterone acetate, GnRH agonist, and prednisone on the feasibility of
      performing nerve-sparing radical prostatectomy (RP) in men with high-risk prostate cancer
      (PCa).

      OUTLINE: Patients are randomized to 1 of 3 treatment arms.

      ARM I: Patients receive androgen receptor antagonist ARN-509 orally (PO) daily for 3 months.
      Patients then undergo radical prostatectomy.

      ARM II: Patients receive GnRH agonist subcutaneously (SC) on day 1, androgen receptor
      antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and
      prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.

      ARM III: Patients undergo radical prostatectomy.

      After completion of study treatment, patients are followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-surgical potency rate defined as proportion of patients with International Index of Erectile Function score &gt;= 17</measure>
    <time_frame>At 12 months</time_frame>
    <description>Each of the experimental arms will be compared to the surgery-only arm, so each test will be a 2.5% level one-sided test to control for the fact that there are two comparisons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume on pelvic MRI after neoadjuvant therapy</measure>
    <time_frame>Baseline to week 13</time_frame>
    <description>Will be correlated with clinical outcomes before and after androgen receptor antagonist ARN-509 or androgen receptor antagonist ARN-509, GnRH agonist, prednisone plus abiraterone acetate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with biochemical recurrence defined using the Prostate Cancer Clinical Trials Working Group 2 definition</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pathological T0</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with positive surgical margins</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative continence rate as determined by the American Urological Association Symptom Score (AUAss)</measure>
    <time_frame>Up to 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative continence rate as determined by the Sexual Health Inventory for Men</measure>
    <time_frame>Up to 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative continence rate as determined by the Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>Up to 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the AUAss questionnaires</measure>
    <time_frame>Up to 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the EPIC questionnaires</measure>
    <time_frame>Up to 24 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Stage II Prostate Adenocarcinoma</condition>
  <condition>Stage III Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (androgen receptor ARN-509, radical prostatectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (radical prostatectomy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgen Receptor Antagonist ARN-509</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (androgen receptor ARN-509, radical prostatectomy)</arm_group_label>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <other_name>ARN-509</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gonadotropin-releasing Hormone Analog</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <other_name>GnRH Agonist</other_name>
    <other_name>GnRH Analog</other_name>
    <other_name>Gonadotropin-Releasing Hormone Agonist</other_name>
    <other_name>Gonadotropin-Releasing Hormone Analogue</other_name>
    <other_name>LH-RH agonist</other_name>
    <other_name>LH-RH Analogs</other_name>
    <other_name>LHRH Agonist</other_name>
    <other_name>luteinizing hormone-releasing hormone agonist</other_name>
    <other_name>Luteinizing Hormone-Releasing Hormone Analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (androgen receptor ARN-509, radical prostatectomy)</arm_group_label>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <arm_group_label>Arm III (radical prostatectomy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (androgen receptor ARN-509, radical prostatectomy)</arm_group_label>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <arm_group_label>Arm III (radical prostatectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <description>Undergo radical prostatectomy</description>
    <arm_group_label>Arm I (androgen receptor ARN-509, radical prostatectomy)</arm_group_label>
    <arm_group_label>Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)</arm_group_label>
    <arm_group_label>Arm III (radical prostatectomy)</arm_group_label>
    <other_name>Prostatovesiculectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the prostate and: Gleason &gt; 8 OR prostatic
             specific antigen (PSA) &gt; 20 and more than 1 positive core

          -  Patients with Eastern Cooperative Oncology Group performance scale (ECOG PS) 0 or 1

          -  Clinical stage T3 or less as demonstrated by abdominal/pelvic computed tomography (CT)
             or magnetic resonance imaging (MRI) will be selected as the prostate is resectable

          -  Hemoglobin &gt;= 9.0 g/dL, independent of transfusion and/or growth factors within 3
             months prior to randomization

          -  Platelet count &gt;= 100,000 x 10^9/uL independent of transfusion and/or growth factors
             within 3 months prior to randomization

          -  Serum albumin &gt;= 3.0 g/dL

          -  Glomerular filtration rate (GFR) &gt;= 45 mL/min

          -  Serum potassium &gt;= 3.5 mmol/L

          -  Serum total bilirubin =&lt; 1.5 × upper limit of normal (ULN) (Note: In subjects with
             Gilbert's syndrome, if total bilirubin is &gt; 1.5 × ULN, measure direct and indirect
             bilirubin and if direct bilirubin is =&lt; 1.5 × ULN, subject may be eligible)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 2.5 × ULN

          -  Medications known to lower the seizure threshold must be discontinued or substituted
             at least 4 weeks prior to study entry

          -  Agrees to use a condom (even men with vasectomies) and another effective method of
             birth control if he is having sex with a woman of childbearing potential or agrees to
             use a condom if he is having sex with a woman who is pregnant while on study drug and
             for 3 months following the last dose of study drug; must also agree not to donate
             sperm during the study and for 3 months after receiving the last dose of study drug

        Exclusion Criteria:

          -  Clinical stage T4 (invasion into rectum or ureters) significantly increases the
             morbidity of the surgery

               -  Patients with rectal or ureteral invasion will be considered to have unresectable
                  disease

          -  History of any of the following:

               -  Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke
                  within 1year to randomization, brain arteriovenous malformation, Schwannoma,
                  meningioma, or other benign central nervous system [CNS] or meningeal disease
                  which may require treatment with surgery or radiation therapy)

               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart
                  failure, arterial within 6 months prior to randomization

               -  Venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident
                  including transient ischemic attacks) within 6 months prior to randomization

               -  Clinically significant ventricular arrhythmias within 6 months prior to
                  randomization

          -  Metastatic prostate cancer

          -  Baseline moderate or severe hepatic impairment (Child-Pugh class B or C)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaac Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertram Yuh</last_name>
      <phone>626-394-2383</phone>
      <email>byuh@coh.org</email>
    </contact>
    <investigator>
      <last_name>Bertram Yuh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaac Y. Kim</last_name>
      <phone>732-235-2043</phone>
      <email>kimiy@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Isaac Y. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Androgen Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

